首页> 美国卫生研究院文献>Cell Proliferation >The cell cycle: a review of regulation deregulation and therapeutic targets in cancer
【2h】

The cell cycle: a review of regulation deregulation and therapeutic targets in cancer

机译:细胞周期:癌症的调控放松调控和治疗目标的审查

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The cell cycle is controlled by numerous mechanisms ensuring correct cell division. This review will focus on these mechanisms, i.e. regulation of cyclin‐dependent kinases (CDK) by cyclins, CDK inhibitors and phosphorylating events. The quality checkpoints activated after DNA damage are also discussed. The complexity of the regulation of the cell cycle is also reflected in the different alterations leading to aberrant cell proliferation and development of cancer. Consequently, targeting the cell cycle in general and CDK in particular presents unique opportunities for drug discovery. This review provides an overview of deregulation of the cell cycle in cancer. Different families of known CDK inhibitors acting by ATP competition are also discussed. Currently, at least three compounds with CDK inhibitory activity (flavopiridol, UCN‐01, roscovitine) have entered clinical trials.
机译:细胞周期受多种机制控制,可确保正确的细胞分裂。本文将重点探讨这些机制,即细胞周期蛋白,CDK抑制剂和磷酸化事件对细胞周期蛋白依赖性激酶(CDK)的调节。还讨论了DNA损伤后激活的质量检查点。细胞周期调节的复杂性还反映在导致异常细胞增殖和癌症发展的不同变化中。因此,一般针对细胞周期,特别是针对CDK,为药物发现提供了独特的机会。这篇综述概述了癌症中细胞周期的失调。还讨论了由ATP竞争作用的已知CDK抑制剂的不同家族。目前,至少有三种具有CDK抑制活性的化合物(黄酮哌啶醇,UCN-01,roscovitine)已进入临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号